Chemotherapy-Induced Anagen Effluvium: Diffuse or Patterned?

Trüeb, Ralph M.

doi:10.1159/000102025

Cited by 30 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,28,29 Growing (anagen) hairs decreased, reaching a low point with 25 AE 21 hairs cm À2 at w6 of chemotherapy, compared with 228 AE 52 hairs cm À2 at baseline, and remaining at a low level between w6 and w18 (Fig. 8,28,29 Growing (anagen) hairs decreased, reaching a low point with 25 AE 21 hairs cm À2 at w6 of chemotherapy, compared with 228 AE 52 hairs cm À2 at baseline, and remaining at a low level between w6 and w18 (Fig.…”

Section: Discussionmentioning

confidence: 99%

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Paclitaxel and docetaxel rank among the top CIA-inducing drugs [110, 111], chiefly by a mechanism that induces dystrophic anagen effluvium [112, 113]. The onset is typically after the first treatment cycle, whether or not in an adjuvant treatment setting.…”

Section: Hair and Nail Changesmentioning

confidence: 99%

“…CIA represents one of the most distressing adverse events of taxanes, affecting the scalp in a diffuse pattern (Grade 2) in at least 60% of treated patients [6, 8, 9]. Other hair-bearing areas (eyelashes, eyebrows, beard, axillae, pubis, and body) may also be involved, especially when the treatment is prolonged, involves higher doses, or entails multiple exposures [1, 112]. …”

Section: Hair and Nail Changesmentioning

confidence: 99%

Dermatological adverse events with taxane chemotherapy

Sibaud

LeBoeuf

Roché

et al. 2016

European Journal of Dermatology

189

179

View full text Add to dashboard Cite

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

show abstract

“…dystrophic anagen effluvium and telogen effluvium. [15] Accordingly, the hair may fall out very quickly in clumps or gradually depending on the mitotic activity of the hair follicle at the moment of the insult.…”

Section: Etiopathogenesis Etiopathogenesismentioning

confidence: 99%

Anagen effluvium

Kanwar¹,

Narang²

2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Disturbances of hair follicle cycling lie at the heart of most hair growth disorders, and have dramatic effects on visible hair growth and shedding. The two common disorders due to aberration in hair follicle cycling are telogen and anagen effluvium. Though a lot of literature addresses the problem of telogen effluvium, there are not many reviews on anagen effluvium or anagen hair loss. Anagen effluvium is considered synonymous with chemotherapy-induced alopecia and other causes are rarely considered. In this review, we try to discuss the etiopathogenesis, clinical presentation, differentials, and management issues in anagen effluvium. Anagen effluvium is the abrupt loss of hairs that are in their growing phase (anagen) due to an event that impairs the mitotic or metabolic activity of hair follicle. Chemotherapy, radiation and toxic chemicals, and sometimes inflammatory diseases like alopecia areata and pemphigus are also capable of diminishing the metabolic activity of hair follicles resulting in anagen hair loss. Although it is reversible, and hair regrowth occurs after a delay of 1-3 months; sometimes it can lead to permanent alopecia and can be psychologically devastating with negative impact on individual perceptions of appearance, body image, sexuality, and self-esteem. For some patients, the emotional trauma may be so severe that it may lead to discontinuing or refusing therapy that might otherwise be beneficial. In such cases, a psychosomatic approach as well as empathic consideration of the patients concerns and fears as well as the provision of practical medical-aesthetic and styling tips are equally important and can be integrated in management.

show abstract

Chemotherapy-Induced Anagen Effluvium: Diffuse or Patterned?

Cited by 30 publications

References 5 publications

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

Dermatological adverse events with taxane chemotherapy

Anagen effluvium

Contact Info

Product

Resources

About